Literature DB >> 2944955

Regulation of the secondary in vitro antibody response by endogenous natural killer cells: kinetics, isotype preference, and non-identity with T suppressor cells.

C P Robles, S B Pollack.   

Abstract

Our previous studies had demonstrated that depletion of endogenous natural killer (NK) cells resulted in an augmented primary antibody response in vivo and in vitro. We have now examined the effect of NK cell depletion on the in vitro secondary response to antigen. Treatment of primed murine spleen cells with anti-NK-1.1 allo-antibody and complement before culture resulted in a significant increase in the magnitude of the antigen-specific plaque-forming cell (PFC) response. This treatment did not affect the proportions of Lyt-2+, L3T4+, or sIg+ cells in the population, however, indicating that the augmentation in PFC was not due to changes in the ratio of T to B cells. Removal of endogenous NK cells had a greater effect on the IgG (indirect) PFC response (100 to 200% increase) than on the IgM (direct) PFC response (25 to 50% increase). In contrast, removal of Lyt-2+ cells before culture affected the IgM and IgG responses similarly. Moreover, the kinetics of augmentation differed between cultures depleted of Lyt-2+ cells and those depleted of NK-1.1+ cells. NK cells appeared to act earlier in the response than did T suppressor cells. The NK-1.1+ cells involved in antibody regulation were not involved in the generation of the in vitro derived T suppressor cells. The conclusion that the regulation of the antibody response by NK-1.1+ cells is distinct from that involving T suppressor cells was confirmed in experiments in which removal of both regulatory cell populations resulted in an increase in PFC that was greater than in cultures depleted of either NK or T suppressor cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944955

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Suppression of in vitro immunoglobulin synthesis by CD16(Leu11a)+ CD56 (NKH1,Leu19)+non-T lineage NK cells; lack of suppression of cells from immunodeficient patients.

Authors:  T Morio; S Nonoyama; J Yata
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Impaired regulation of natural killer cells in immunoglobulin synthesis by peripheral blood mononuclear cells from patients with ulcerative colitis.

Authors:  T Kawase; K Kusugami; H Matsunaga; T Matsuura; K Morise
Journal:  Gastroenterol Jpn       Date:  1990-10

3.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

4.  Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38.

Authors:  T Bourne; M Zukowska-Cooper; M R Salaman; M H Seifert; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

5.  Human natural killer (NK) cells produce a late-acting B-cell differentiation activity.

Authors:  H Kimata; E H Sherr; A Saxon
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

6.  Early detection of metastasis by alterations in the cellular immune system in the murine liver and blood.

Authors:  N Freudenberg; P Rahner; C Darda; A Kiss; G Veres; T Nees; R Lamers; U N Riede; C Kortsik; M Schubert; K Frenzer-Welle
Journal:  Virchows Arch       Date:  1996-06       Impact factor: 4.064

7.  Identification of a subset of murine natural killer cells that mediates rejection of Hh-1d but not Hh-1b bone marrow grafts.

Authors:  C L Sentman; J Hackett; V Kumar; M Bennett
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

Review 8.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.